Business
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
LOS ANGELES, February 26, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience’s operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual prop
About this update from Niagen Bioscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2250,"height":450,"url":"https://media.zenfs.com/en/business-wire.com/c8f1064a7f96e2d1364a1803b579845d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xHeVrlVxY.e5CYRD2DF0ng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c8f1064a7f96e2d1364a1803b579845d","width":960,"height":192},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/czeMyotvwdqvDclSAZuBdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c8f1064a7f96e2d1364a1803b579845d","width":1200,"height":240}},"lazy":false},{"type":"text","content":"Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, February 26, 2026--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience’s operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry.","length":579,"tagName":"p"},{"type":"text","content":"Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best—advancing NAD+ science and delivering clinically proven, patented Niagen® solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders."","length":440,"tagName":"p"},{"type":"text","content":"LGC Standards is a division of LGC Group, a global leader in life sciences, diagnostics, and analytical solutions. The LGC Standards business provides reference materials, research chemicals, and proficiency testing to ensure accuracy and reliability in laboratories and manufacturing.","length":285,"tagName":"p"},{"type"...